Highlights

• In Q2FY26, Apollo Hospitals’ PAT increased 26% year-on-year to ₹4,772 million.
• In H1FY26, consolidated revenue rose 14% to ₹121,456 million.
• EBITDA for Q2FY26 grew 15% to ₹9,412 million.

Apollo Hospitals Enterprise Limited (NSE:APOLLOHOSP) has released second quarter FY26 results, with consolidated revenue, EBITDA, and profit after tax (PAT) all registering double-digit growth. The company continues to advance its expansion plans across India while introducing new clinical services and diagnostic capabilities. Shares were trading at ₹7,715.00, down 0.86% in early morning trades on 7 November 2025.

Consolidated Financial Performance

In Q2FY26, Apollo Hospitals’ consolidated revenue grew 13% year-on-year to ₹63,035 million. EBITDA rose 15% to ₹9,412 million, while PAT surged 26% to ₹4,772 million. For the first half of FY26, consolidated revenue reached ₹121,456 million, a 14% increase from H1FY25. EBITDA expanded 20% to ₹17,931 million, and PAT climbed 33% to ₹9,100 million.

Healthcare Services Segment

Apollo’s Healthcare Services (HCS) segment recorded revenue growth of 9% in Q2FY26, supported by a 2% increase in inpatient volume and a 7% improvement in pricing and case mix. Average revenue per inpatient increased by 9% to ₹173,318. A reduction in patients from Bangladesh contributed to a 1% impact on segment revenue. Revenue growth was partly offset by a lower number of medical admissions compared to Q2FY25, which had higher seasonal admissions. This was mitigated by a 14% increase in revenue from specialized treatments offered through CONGO specialties.

The company reported a return on capital employed (ROCE) of 30.3% for the HCS segment.

Expansion and Clinical Initiatives

Apollo Hospitals continues to pursue growth through capacity expansion and bolt-on acquisitions in select Tier-1 cities and metro areas. The company plans to add approximately 4,400 beds, of which around 3,600 will be census beds over the next five years.

Clinically, Apollo has introduced new therapies including PEMF Ion Therapy, Infrared, Stem Cell, and Exosome Therapy at its Bengaluru clinic. Diagnostic services have expanded to include advanced fetal chromosomal screening, genetic testing for muscular dystrophy, extended HPV genotyping, and whole genome sequencing. Awareness campaigns such as the PLAC Test for heart blockage and Apollo Dialysis Nutrition Week aim to enhance patient engagement.

Digital and Operational Initiatives

Apollo HealthCo has improved pharma order economics, boosted diagnostic GMV through expansion into 18 new cities, and strengthened hospital penetration through multi-specialty services. Insurance operations have also expanded across cities, products, and networks, leveraging technology and recruitment to increase reach.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

Copyright 2026 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.